Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: A homozygote for the SLCO1B1*15 allele

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 666-668

  Takane, Hiroshi ^a   Miyata, Masanori ^b   Burioka, Naoto ^b   Kurai, Jun ^b   Fukuoka, Yasushi ^b   Suyama, Hisashi ^b   Shigeoka, Yasushi ^b   Otsubo, Kenji ^a   Ieiri, Ichiro ^c   Shimizu, Eiji ^b  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Irinotecan; Pharmacogenetics; Pharmacokinetics; SLCO1B1; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALLOPURINOL; BICARBONATE; CISPLATIN; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LANSOPRAZOLE; MAGNESIUM OXIDE; METOCLOPRAMIDE; MOSAPRIDE CITRATE; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PROTEIN; REBAMIPIDE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DISPOSITION; GENE; GENETIC SCREENING; GENETIC VARIABILITY; GLUCURONOSYLTRANSFERASE 1A1 GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; LEUKOPENIA; LUNG CANCER; NEUTROPENIA; ORGANIC ANION TRANSPORT POLYPEPTIDE 1B1 GENE; ORGANIC ANION TRANSPORTER 2 GENE; PRIORITY JOURNAL;

ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, TOXIC; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC;

EID: 34848899579     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181357364     Document Type: Article

References (16)

1. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.
2. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
3. Mathijssen RHJ, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194.
4. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.
5. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004;75:501-515.
6. Kitagawa C, Ando M, Ando Y, et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics. 2005;15:35-41.
7. Nozawa T, Minami H, Sugiura S, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33:434-439.
8. Nishizato Y Nishizato, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73:554-565.
9. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973;4:31-42.
10. Rivory LP, Robert J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol. 1995;36:176-179.
11. Sparreboom A, de Bruijn P, de Jonge JA, et al. Liquid chromatographic determined of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B. 1998;721:225-235.
12. 14C] CPT-11 in cancer patients. Drug Metab Dispos. 2000;28:423-433.
13. Kim S, Nakamura T, Saito Y, et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet. 2003;18:327-332.
14. Santos A, Zanetta S, Createil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000;5:2012-2020.
15. Kehrer DFS, Mathijssen RHJ, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol. 2002;20:3122-3129.
16. Xiang X, Jada SR, Li HH, et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics. 2006;16:683-691.